Anifrolumab is used to treat systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues, causing inflammation and damage to joints, skin, kidneys, and other organs.[2] Saphnelo is currently approved and in use across 11 indications[4].[1]
Saphnelo is one of 287 monoclonal antibody programs targeting Systemic Lupus Erythematosus. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
836 competitors in Ovarian Cancer
Saphnelo
Avastin
Trodelvy
Nolvadex
Neupogen
H2 Receptor Antagonist
SHR-A1811
Karenitecin
Batiraxcept
TLK286
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 30, 2021
SAPHNELO
BLA BLA761123
Apr 24, 2026
SAPHNELO
BLA BLA761451
Sources
Details